Aptuit LLC announced that the company has reached an agreement on a multiyear extension of its strategic partnership with GlaxoSmithKline (GSK) for dedicated drug development work at The Aptuit Center for Drug Discovery & Development in Verona, Italy. The Verona site – formerly known as GSK’s Medicines Research Centre – was acquired by Aptuit from GSK in 2010.
Timothy C. Tyson, Chairman, Aptuit LLC said, “This multiyear extension of our partnership with GSK reaffirms that our Verona site continues to deliver scientific excellence that is recognized by our customers. Since we finalized our original agreement with GSK in 2010, we have successfully transformed the Verona site from a pharmaceutical research center to a world-class drug discovery and development outsourcing capability.”
Mr. Tyson explained that during the two years since the Verona site became part of Aptuit it has effectively transitioned to a lean, flexible, customer-focused pharmaceutical services operation. To date, the Verona site has had approximately 50 successful audits and has delivered work for more than 90 clients. Mr. Tyson added, “Aptuit initiatives in Verona, such as Lean Six Sigma, are resulting in productivity benefits across our business lines. The high level of quality and regulatory compliance demonstrated in our work has been noticeable to the more than 200 customers who have visited the site since 2010.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.